Valentı́n Fuster

Dr. Borja Ibáñez

Interventional / Structural Cardiology · Instituto de Salud Carlos III

8h

“

The next step is to determine whether strategies to reduce inflammation can help halt the atherosclerotic process. Previous clinical trials in this area generated controversial results, but they were conducted in the context of much more advanced atherosclerosis. Targeting inflammation at earlier stages may turn out to be more beneficial than later interventions, although this is something we need to test.

Michael E. Farkouh

Interventional / Structural Cardiology · Cedars-Sinai Smidt Heart Institute

9d

“

Our study report supports the use of CABG surgery over PCT; however the results should not be overly simplified. The management of patients with diabetes and coronary disease should still be personalized to include an assessment of surgical risk and benefits as well as patient preferences.

Borja Ibáñez

Interventional / Structural Cardiology · Instituto de Salud Carlos III

10d

“

conventional risk factors (blood cholesterol, hypertension, smoking, etc.) allow a broad prediction of the population risk of severe cardiovascular events (infarction or stroke); however, individualized predictions based on these risk factors are not very accurate. Now, with the ability to directly visualize atherosclerotic plaques and quantify their number and size in the body, we will be able to predict risk more accurately. The presence and extent of atherosclerosis gives direct information about how risk factors affect the arteries in each individual.

Michael Farkouh

Interventional / Structural Cardiology · Cedars-Sinai Smidt Heart Institute

2w

“

We tried to look at the predictors of who had a better outcome, and in the bypass patients the SYNTAX score really didn't make much difference. The SYNTAX score didn't drive outcomes. It did somewhat in the PCI group, but not in the comparison with PCI versus CABG. It had only a modest impact. So what this tells us if we're going to make a decision to perform PCI or CABG, the SYNTAX shouldn't be driving the decision.

David Kandzari

Interventional / Structural Cardiology · Piedmont Atlanta Hospital

2w

“

this is the largest sham-controlled, randomized experience we have with this method of renal denervation, and it confirms the biologic proof of principle or the efficacy of renal denervation to reduce blood pressure

“

The new guidelines help to establish the type of patient population for which the drug is best suited. Dofetilide is one of the few drugs that can be used in heart failure patients.

Dr. Sergio Raposeiras-Roubin

Interventional Cardiology · Centre Hospitalier de Luxembourg

3w

“

Previous trials have provided evidence for SGLT-2 inhibitors in patients with a variety of other conditions but have excluded patients with valvular heart disease. Based on our study, if you have a patient undergoing TAVI who is at risk of heart failure, it is important to treat them with dapagliflozin or another SGLT-2 inhibitor. These are safe drugs and have a lot of benefit.

Xavier Rosselló

General Cardiology · Universitat Autònoma de Barcelona

2w

“

Our findings extend the known benefits of these agents in MI patients with reduced LVEF to the subgroup with mildly reduced LVEF. Further research should now focus on patients with preserved LVEF (>50%).

“

There is a need for a complete change in the timing of when we deliver care. Until now, the clinical community has focused on cardiovascular disease, which typically manifests in the later stages of life. Now, we need to focus our care in the opposite stage of life--we need start promoting health at the earliest years, as early as 3 to 5 years old, in order to prevent cardiovascular disease.